New lithium formula could mean fewer side effects for brain disorders
NCT ID NCT06921590
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new crystallized form of lithium (AL001) against standard lithium carbonate in 6 healthy adults. Participants take each drug for 14 days and undergo MRIs and blood draws to compare how much lithium reaches the brain. The goal is to see if AL001 is safer and delivers more lithium to the brain, which could lead to better treatments for brain conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AL001 (crystallized lithium) and lithium carbonate
What this could lead to
If AL001 delivers more lithium to the brain with fewer side effects, it could point toward a better-tolerated treatment for conditions like bipolar disorder or Alzheimer's.
What could go wrong
This is a very early, tiny study in just 6 healthy people. It only measures how the drug behaves, not whether it works for any disease. Results may not apply to patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States